ArticleSpringerPlus2016

cMET inhibitor crizotinib impairs angiogenesis and reduces tumor burden in the C3(1)-Tag model of basal-like breast cancer.

Alyssa J Cozzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.